Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[HIV drug resistance].
Marcelin AG, Calvez V. Marcelin AG, et al. Rev Prat. 2006 May 15;56(9):978-86. Rev Prat. 2006. PMID: 16775978 Review. French.
Resistance to novel drug classes.
Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Marcelin AG, et al. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Curr Opin HIV AIDS. 2009. PMID: 20048722 Review.
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C. Caby F, et al. Among authors: marcelin ag. Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502. Scand J Infect Dis. 2010. PMID: 20222846
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: marcelin ag. Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7. Antimicrob Agents Chemother. 2010. PMID: 20530226 Free PMC article.
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F. Malet I, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2011 Jul;66(7):1481-3. doi: 10.1093/jac/dkr152. Epub 2011 Apr 7. J Antimicrob Chemother. 2011. PMID: 21474479 Free article.
The future of integrase inhibitors of HIV-1.
Malet I, Calvez V, Marcelin AG. Malet I, et al. Among authors: marcelin ag. Curr Opin Virol. 2012 Oct;2(5):580-7. doi: 10.1016/j.coviro.2012.08.005. Epub 2012 Sep 12. Curr Opin Virol. 2012. PMID: 22980926 Review.
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group. Marcelin AG, et al. Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4. Int J Antimicrob Agents. 2013. PMID: 23562640
467 results